Intracellular disposition of fludarabine triphosphate in human natural killer cells
- PMID: 18781301
- PMCID: PMC2648818
- DOI: 10.1007/s00280-008-0829-0
Intracellular disposition of fludarabine triphosphate in human natural killer cells
Abstract
Purpose: Fludarabine is a key component of several reduced-intensity conditioning regimens for hematopoietic cell transplantation (HCT). Shortly after reduced-intensity conditioning, the percent of donor natural killer (NK) cells has been associated with progression-free survival. Insufficient suppression of the recipient's NK cells by fludarabine may lead to lower donor chimerism; however, the effect of fludarabine upon NK cells is poorly understood. Thus, in purified human NK cells we evaluated the uptake and activation of fludarabine to its active metabolite, fludarabine triphosphate (F-ara-ATP), and assessed the degree of interindividual variability in F-ara-ATP accumulation.
Methods: Intracellular F-ara-ATP was measured in purified NK cells isolated from healthy volunteers (n = 6) after ex vivo exposure to fludarabine. Gene expression levels of the relevant transporters and enzymes involved in fludarabine uptake and activation were also measured in these cells.
Results: F-ara-ATP accumulation (mean +/- SD) was 6.00 +/- 3.67 pmol/1 x 10(6) cells/4 h, comparable to average levels previously observed in CD4(+) and CD8(+) T-lymphocytes. We observed considerable variability in F-ara-ATP accumulation and mRNA expression of transporters and enzymes relevant to F-ara-ATP accumulation in NK cells from different healthy volunteers.
Conclusions: Human NK cells have the ability to form F-ara-ATP intracellularly and large interindividual variability was observed in healthy volunteers. Further studies are needed to evaluate whether F-ara-ATP accumulation in NK cells are associated with apoptosis and clinical outcomes.
Figures
Similar articles
-
Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.Cancer Chemother Pharmacol. 2015 Jul;76(1):85-96. doi: 10.1007/s00280-015-2768-x. Epub 2015 May 17. Cancer Chemother Pharmacol. 2015. PMID: 25983023 Free PMC article.
-
A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients.Cancer Chemother Pharmacol. 2009 Feb;63(3):391-401. doi: 10.1007/s00280-008-0748-0. Epub 2008 Apr 9. Cancer Chemother Pharmacol. 2009. PMID: 18398611 Free PMC article.
-
Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.Leuk Lymphoma. 1993 May;10(1-2):49-56. doi: 10.3109/10428199309147356. Leuk Lymphoma. 1993. PMID: 8374523 Clinical Trial.
-
Cellular and clinical pharmacology of fludarabine.Clin Pharmacokinet. 2002;41(2):93-103. doi: 10.2165/00003088-200241020-00002. Clin Pharmacokinet. 2002. PMID: 11888330 Review.
-
Genetic factors influencing cytarabine therapy.Pharmacogenomics. 2009 Oct;10(10):1657-74. doi: 10.2217/pgs.09.118. Pharmacogenomics. 2009. PMID: 19842938 Free PMC article. Review.
Cited by
-
Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant. 2017 Jul;52(7):977-983. doi: 10.1038/bmt.2017.79. Epub 2017 May 8. Bone Marrow Transplant. 2017. PMID: 28481355 Free PMC article.
-
Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.Cancer Chemother Pharmacol. 2015 Jul;76(1):85-96. doi: 10.1007/s00280-015-2768-x. Epub 2015 May 17. Cancer Chemother Pharmacol. 2015. PMID: 25983023 Free PMC article.
-
Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities.Pharmacol Ther. 2022 Dec;240:108300. doi: 10.1016/j.pharmthera.2022.108300. Epub 2022 Oct 22. Pharmacol Ther. 2022. PMID: 36283452 Free PMC article. Review.
-
Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS.J Pharm Biomed Anal. 2013 Dec;86:198-203. doi: 10.1016/j.jpba.2013.08.007. Epub 2013 Aug 23. J Pharm Biomed Anal. 2013. PMID: 24013121 Free PMC article.
-
Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.Biol Blood Marrow Transplant. 2017 Oct;23(10):1701-1713. doi: 10.1016/j.bbmt.2017.06.021. Epub 2017 Jul 3. Biol Blood Marrow Transplant. 2017. PMID: 28684371 Free PMC article. Clinical Trial.
References
-
- Deeg HJ, Maris MB, Scott BL, Warren EH. Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia. 2006;20:1701–5. - PubMed
-
- Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–63. - PubMed
-
- Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J, Molldrem J, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park) 2003;17:94–100. discussion 103-7. - PubMed
-
- Storb R. Mixed allogeneic chimerism and graft-versus-leukemia effects in acute myeloid leukemia. Leukemia. 2002;16:753–4. - PubMed
-
- Baron F, Storb RG, Sandmaier B, Gisburne S, Shin S, Stroup P, Baker J, Maris M, Maloney D, Heimfeld S, Grumet FC, Chauncey T, Blume K, Little MT. Assessing Donor Chimerism Level Among CD3 T, CD4 T, CD8 T AND NK Cells Predicts Subsequent Graft Rejection, GVHD and Relapse After Allogeneic HCT with Nonmyeloablative Conditioning; ASBMT Tandem BMT Meetings; 2005; T.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials